Marisa Wexler, MS,  senior science writer—

September is CMT Awareness Month, and organizations are working to increase visibility of Charcot-Marie-Tooth (CMT) disease — a disease that often goes unseen. “CMT is not invisible because it is rare. It is invisible because no one talks about it,” the Charcot-Marie-Tooth Association stated on its awareness month…

The Zeus KAFO, a new device from Icarus Medical Innovations, aims to support mobility in people with lower limb weakness, instability, or paralysis due to conditions such as Charcot-Marie-Tooth disease (CMT). The Zeus device is a knee-ankle-foot orthosis (KAFO), meaning it’s worn from the…

The Muscular Dystrophy Association‘s (MDA) annual Clinical & Scientific Conference kicked off over the weekend, bringing together patients, caregivers, researchers, clinicians, academics, advocates, and industry leaders to discuss the latest in science and care related to a range of neuromuscular diseases. This year’s conference will bring together hundreds…

The CMT Association is investing $423,000 in the Genesis database to help improve diagnoses of Charcot-Marie-Tooth disease (CMT). The investment, part of the association’s Strategy to Accelerate Research program known as CMTA-STAR, is intended to help researchers in identifying additional genes whose mutations are causes of CMT.

A team of U.S. researchers is calling for routine screening for hip dysplasia — when the bones in the hip joint don’t fit together correctly, causing instability — among children with Charcot-Marie-Tooth disease (CMT), after their work revealed it to be a common but underrecognized problem in young people…

In Charcot-Marie-Tooth disease (CMT), a type of support cell called Schwann cells help to repair nerve injury to limit the severity of the disease, a new study suggests. The finding suggests that therapies aiming to activate certain pathways in these cells may be beneficial in CMT and other peripheral…

The Charcot-Marie-Tooth Association (CMTA) has given a $225,483 award to support the development of treatments for Charcot-Marie-Tooth disease type 2E (CMT2E). The work is also being supported by the Muscular Dystrophy Association. The project will be led by Mario Saporta, MD, PhD, clinical neurologist and researcher at…

The CMT Research Foundation (CMTRF) is joining forces with Nanite, a biotechnology company, to work toward the development of new gene therapies for Charcot-Marie-Tooth disease (CMT). Nanite will use its artificial intelligence platform to design delivery vehicles that can get genetic medicines to certain cells in the…

Electrical stimulation reduced toxic PMP22 protein clumping and promoted myelin-making activity in a cell model of Charcot-Marie-Tooth disease type 1A (CMT1A), a new study reports. “We expect that the findings … will play a significant role in the potential clinical translation of an electroceutical [electricity-based] treatment for CMT1A disease,”…

A novel mutation in the GJB1 gene was found to cause X-linked Charcot-Marie-Tooth disease (CMT) in a new study. “Our results expand the spectrum of mutations in GJB1 known to be associated with [X-linked CMT] and contribute to the diagnosis of CMT and clinical genetic counseling,” the researchers wrote. The…